Restricted accessResearch articleFirst published online 2004-06
Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment
Matrix metalloproteinases (MMPs) have been identified as mediators of brain injury in multiple sclerosis (MS) and it has recently been reported that treatment of MS patients with interferon-beta (IFN-b) reduces MMP-9 serum levels and in vitro release from monocytes. We investigated whether IFN-b is able to modulate the expression of MMPs in glial cell cultures. Rat microglial and astrocyte cultures were treated with different doses of IFN-b, then activated by exposure to LPS. In another set of experiments cells were simultaneously activated with LPS and treated with IFN-b. C ulture supernatants collected from astrocytes and microglia were subjected to zymography for the assessment of MMP-2 and MMP-9. Increased amounts of MMP-9 and MMP-2 were observed in supernatants from LPS-treated astrocytes in comparison with supernatants from nontreated control cells. MMP-9 also increased in LPS-treated microglia. The treatment of astrocytes and microglia with IFN-b inhibited dose-dependently the expression of both MMP-2 and MMP-9 in LPS-treated astrocytes and of MMP-9 in LPS-treated microglia. These results demonstrate a modulating effect of IFN-b on the release of MMPs from C NS cells. This effect represents an additional mechanism by which IFN-b may decrease the development of new C NS lesions in the course of MS.
Raine CS , Cannella B , Duijvestijn AM , Cross AH.Homing to central nervous system vasculature by antigen-specific lymphocytes. II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination . Lab Invest1990; 63: 476-489 .
2.
Hickey WF , Hsu BL , Kimura H.T-lymphocyte entry into the central nervous system . J Neurosci Res1991; 28: 254-260 .
3.
Woessner JF.Matrix metalloproteinases and their inhibitors in connective tissue remodelling . FASEB J1991; 5: 2145-2154 .
4.
Van den Steen PE , Dubois B , Nelissen I , Rudd PM , Dwek RA , Opdenakker G.Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9) . Crit Rev Biochem Mol Biol2002; 37: 375-536 .
5.
Gottschall PE , Yu X.Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes . J Neurochem1995; 64: 1513-1520 .
6.
Colton CA , Keri JE , Chen WT , Monsky WL.Protease production by cultured microglia: substrate gel analysis and immobilized matrix degradation . J Neurosci Res1993; 35: 297-304 .
7.
Gottschall PE , Yu X , Bing B.Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture . J Neurosci Res1995; 42: 335-342 .
8.
Maeda A , Sobel RA.Matrix metalloproteinases in the normal human central nervous system, microglial nodules and multiple sclerosis lesions . J Neuropathol Exp Neurol1996; 55: 300-309 .
9.
Cuzner ML , Gveric D , Strand C , Loughlin AJ , Paemen L , Opdenakker Get al.The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution . J Neuropathol Exp Neurol1996; 55: 1194-1204 .
10.
Gijbels K , Masure S , Carton H , Opdenakker G.Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders . J Neuroimmunol1992; 41: 29-34 .
11.
Paemen L , Olsson T , Soderstrom M , Van Damme J , Opdenakker G.Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases . Eur J Neurol1994; 1: 55-63 .
12.
Leppert D , Ford J , Stabler G , Grygar C , Lienert C , Huber Set al.Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis . Brain1998; 121: 2327-2334 .
13.
Liuzzi GM , Trojano M , Fanelli M , Avolio C , Fasano A , Livrea Pet al.Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis . Mult Scler2002; 8: 222-228 .
14.
Leppert D , Waubant E , Burk MR , Oksenberg JR , Hauser SL.Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis . Ann Neurol1996; 40: 846-852 .
15.
Stuve O , Dooley NP , Uhm JH , Antel JP , Francis GS , Williams Get al.Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9 . Ann Neurol1996; 40: 853-863 .
16.
Trojano M , Avolio C , Liuzzi GM , Ruggieri M , Defazio G , Liguori Met al.Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS . Neurology1999; 53: 1402-1408 .
17.
Bartholome EJ , Van Aelst I , Koyen E , Kiss R , Willems F , Goldman Met al.Human monocyte-derived dendritic cells produce bioactive gelatinase B: inhibition by IFN-beta . J Interferon Cytokine Res2001; 21: 495-501 .
18.
Proost P , Van Damme J , Opdenakker G.Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein . Biochem Biophys Res Commun1993; 192: 1175-1181 .
19.
Nakajima K , Hamanoue M , Shimojo M , Takei N , Kohsaka S.Characterization of microglia isolated from a primary culture of embryonic rat brain by a simplified method . Biomed Res1989; 10: 411-423 .
20.
Gebicke-Haerter PJ , Bauer J , Schobert A , Northoff H.Lipopolysaccharide-free conditions in primary astrocyte cultures allow growth and isolation of microglial cells . J Neurosci1989; 9: 183-194 .
21.
McCarthy KD , de Vellis J.Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue . J Cell Biol1980; 85: 890-902 .
22.
Liuzzi GM , Santacroce MP , Peumans WJ , Van Damme EJ , Dubois B , Opdenakker Get al.Regulation of gelatinases in microglia and astrocyte cell cultures by plant lectins . Glia1999; 27: 53-61 .
23.
Rosenberg GA.Matrix metalloproteinases in neuroinflammation . Glia2002; 39: 279-291 .
24.
Opdenakker G , Van Damme J.Cytokine-regulated proteases in autoimmune diseases . Immunol Today1994; 15: 103-107 .
25.
Yong VW , Power C , Forsyth P , Edwards DR.Metalloproteinases in biology and pathology of the nervous system . Nat Rev Neurosci2001; 2: 502-511 .
26.
Fosang AJ , Hardingham TE.Isolation of the N-terminal globular protein domains from cartilage proteoglycans. identification of G2 domain and its lack of interaction with hyaluronate and link protein . Biochem J1989; 261: 801-809 .
27.
Lein M , Nowak L , Jung K , Koenig F , Lichtinghagen R , Schnorr Det al.Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood . Clin Biochem1997; 30: 491-496 .
28.
Vos CM , Sjulson L , Nath A , McArthur JC , Pardo CA , Rothstein Jet al.Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures . Exp Neurol2000; 163: 324-330 .
29.
Gearing AJ , Beckett P , Cristodoulou M , Churchill M , Clements J , Davidson AHet al.Processing of tumor necrosis factor-alpha precursor by metalloproteinases . Nature1994; 370: 555-557 .
30.
Chandler S , Miller KM , Clements JM , Lury J , Corkill D , Anthony DCet al.Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview . J Neuroimmunol1997; 72: 155-161 .
31.
Ozenci V , Rinaldi L , Teleshova N , Matusevicius D , Kivisakk P , Kouwenhoven Met al.Metalloproteinases and their tissue inhibitors in multiple sclerosis . J Autoimmun1999; 12: 297-303 .
32.
Anthony DC , Ferguson B , Matyzak MK , Miller KM , Esiri MM , Perry VH.Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke . Neuropathol Appl Neurobiol1997; 23: 406-415 .
33.
Cossins JA , Clements JM , Ford J , Miller KM , Pigott R , Vos Wet al.Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions . Acta Neuropathol (Berl)1997; 94: 590-598 .
34.
Paty DW , Li DK.Interferon beta-1b is effective in relapsingremitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group . Neurology1993; 43: 662-667 .
Yong VW , Chabot S , Stuve O , Williams G.Interferon beta in the treatment of multiple sclerosis: mechanisms of action . Neurology1998; 51: 682-689 .
37.
Uhm JH , Dooley NP , Stuve O , Francis GS , Duquette P , Antel JPet al.Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy . Ann Neurol1999; 46: 319-324 .
38.
Waubant E , Gee L , Bacchetti P , Sloan R , Cotleur A , Rudick Ret al.Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS . J Neuroimmunol2001; 112: 139-145 .
39.
Ma Z , Qin H , Benveniste EN.Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-g and IFN-b: critical role of STAT-1a . J Immunol2001; 167: 5150-5159 .
40.
Sanceau J , Boyd DD , Seiki M , Bauvois B.Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B . J Biol Chem2002; 277: 35766-35775 .
41.
Cuzner ML , Opdenakker G.Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system . J Neuroimmunol1999; 94: 1-14 .
42.
Noronha A , Toscas A , Jensen MA.Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis . J Neuroimmunol1993; 46: 145-153 .
